Clinical Data Survodutide delivers 16.6% weight loss in major phase 3 obesity trial PharmaTimesBoehringer Ingelheim reports significant reductions in weightMetabolic & GLP-1Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) PharmaTimes Boehringer Ingelheim reports significant reductions in weight Metabolic & GLP-1 Read full story Post navigation Previous: Avalyn, in pursuit of better lung drugs, banks $300M in an IPONext: Ray Therapeutics receives EMA PRIME status for gene therapy Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
